GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Cyclically Adjusted PB Ratio

OMER (Omeros) Cyclically Adjusted PB Ratio : (As of May. 27, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Omeros Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Omeros's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Cyclically Adjusted PB Ratio Chart

Omeros Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Omeros Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Omeros's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Omeros's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Cyclically Adjusted PB Ratio falls into.


;
;

Omeros Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Omeros's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Omeros's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-3.678/134.9266*134.9266
=-3.678

Current CPI (Mar. 2025) = 134.9266.

Omeros Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.209 100.684 0.280
201509 -0.237 100.392 -0.319
201512 -0.690 99.792 -0.933
201603 -1.041 100.470 -1.398
201606 -1.247 101.688 -1.655
201609 -0.531 101.861 -0.703
201612 -0.855 101.863 -1.133
201703 -1.095 102.862 -1.436
201706 -1.234 103.349 -1.611
201709 0.192 104.136 0.249
201712 -0.058 104.011 -0.075
201803 -0.605 105.290 -0.775
201806 -1.161 106.317 -1.473
201809 -1.816 106.507 -2.301
201812 -2.043 105.998 -2.601
201903 -2.469 107.251 -3.106
201906 -2.648 108.070 -3.306
201909 -2.825 108.329 -3.519
201912 -2.011 108.420 -2.503
202003 -2.419 108.902 -2.997
202006 -2.958 108.767 -3.669
202009 -1.416 109.815 -1.740
202012 -1.958 109.897 -2.404
202103 -3.565 111.754 -4.304
202106 -3.941 114.631 -4.639
202109 -4.200 115.734 -4.896
202112 0.380 117.630 0.436
202203 -0.079 121.301 -0.088
202206 -0.521 125.017 -0.562
202209 -0.738 125.227 -0.795
202212 1.364 125.222 1.470
202303 0.874 127.348 0.926
202306 0.326 128.729 0.342
202309 -0.222 129.860 -0.231
202312 -0.409 129.419 -0.426
202403 -1.231 131.776 -1.260
202406 -2.150 132.554 -2.188
202409 -2.660 133.029 -2.698
202412 -3.146 133.157 -3.188
202503 -3.678 134.927 -3.678

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Omeros  (NAS:OMER) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Omeros Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Omeros's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Omeros Business Description

Industry
Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Executives
Demopulos Gregory A Md director, 10 percent owner, officer: Chairman, CEO & President 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen officer: VP Finance and CAO 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo officer: See Remarks 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol director 201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon officer: VP Patent and General Counsel 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet director 1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347